For FDA-approved brand-name options, Wegovy injectable starts at $199 per month for new self-pay patients through NovoCare, while Zepbound begins at $299 per month through LillyDirect
Specialists project that commercial availability can commence by 2026, relying on regulatory evaluations and trial outcomes
A meta-analysis conducted in 20211 disclosed a reduction of allcause mortality by 12 percent
"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes" (Press release)
Retatrutide is an investigational peptide currently under clinical development by Eli Lilly and Company
GLP-3 (Reta) 10mg GLP-3 (Retatrutide) is a multi-pathway receptor agonist widely utilized in preclinical research involving metabolic regulation, incretin signaling, glucagon-associated pathways, and energy balance-related biochemical processes